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ABSTRACT
It has been previously reported that in healthy subjects, the acute
reduction of free fatty acids (FFA) levels by acipimox enhances the GH
response to GHRH. In the present study, the GH response to GHRH
was evaluated during acute blockade of lipolysis obtained either by
acipimox or by insulin at different infusion rates. Six healthy subjects
(four men and two women, 25.8 6 1.9 yrs old, mean 6 SE) underwent
three GHRH tests (50 mg iv, at 1300 h) during: 1) iv 0.9% NaCl
infusion (1200–1500 h) after oral acipimox administration (250 mg)
at 0700 h and at 1100 h; 2) 0.1 mUzkg21zmin21 euglycemic insulin
clamp (1200–1500 h) after oral acipimox administration (250 mg at
0700 h and at 1100 h); 3) 0.4 mUzkg21zmin21 euglycemic insulin clamp
(1200–1500 h) after oral placebo administration (at 0700 and 1100 h).
Serum insulin (immunoreactive insulin) levels were significantly
different in the three tests (12 6 2, 100 6 10, 194 6 19 pmol/L, P ,
0.05), plasma FFA were low and similar (0.04 6 0.003, 0.02 6 0.005,
0.02 6 0.003, not significant), and the GH response to GHRH was
progressively lower (4871 6 1286, 2414 6 626, 1076 6 207 mg/Lz120
min), although only test 3 was significantly different from test 1 (P ,
0.05). Pooling the three tests together, a significant negative regres-
sion was observed between mean serum immunoreactive insulin lev-
els and the GH response to GHRH (r 5 20.629, P , 0.01).
Our results indicate that in healthy subjects, acipimox and hyper-
insulinemia produce a similar decrease in FFA levels and that at
similar low FFA, the GH response to GHRH is lower during insulin
infusion than after acipimox. These data suggest that insulin exerts
a negative effect on GH release. Because the insulin levels able to
reduce the GH response to GHRH are commonly observed during the
day, for instance during the postprandial period, we conclude that the
insulin negative effect on GH release may have physiological rele-
vance. (J Clin Endocrinol Metab 82: 2239–2243, 1997)
THE ROLE OF metabolic/hormonal factors in the physio-logical regulation of GH release is only partially known.
Free fatty acids (FFA) inhibit GH release via a negative feedback
(1–7), thought to occur both at the pituitary (6) and at the
hypothalamic level (5). In contrast, the role of insulin is less
clear. Through hypoglycemia, insulin stimulates GH release,
but several pieces of experimental data suggest possible direct
effects of insulin on the GH axis; for instance, insulin receptors
are present in rat hypothalamus (8), and insulin binding sites
have been demonstrated in normal rat pituitary cells [though at
extremely low concentrations (9)], in rat anterior pituitary ad-
enoma cells (10), and in human pituitary adenoma cells (11).
Furthermore, in vitro studies have shown that insulin decreases
GH synthesis, release, and messenger RNA (mRNA) content of
rat pituitary normal and adenoma cells (12–16) and suppresses
GH release from human pituitary adenoma cells (11). Data
available in vivo in normal subjects also suggest an inhibitory
role of insulin on GH release: integrated 24-h GH concentra-
tions are elevated during fasting, i.e. under conditions of low
serum insulin levels (17); during euglycemic insulin clamp, a
reduction of the GH response to GHRH has been observed (18),
whereas during hypoglycemic insulin clamp, the GH response
to hypoglycemia is inversely related to the degree of hyperin-
sulinemia (19).
In studying the effect of insulin per se on GH release, one
is faced with the problem that an increase in insulin levels is
accompanied by a concomitant decrease in FFA levels,
caused by the antilipolytic activity of insulin (20). Because an
acute decrease in FFA levels enhances the GH responsive-
ness to GHRH in healthy subjects (7, 21), this may mask the
concomitant effect of insulin on GH release. On the other
side, the fall of FFA levels after pharmacologic blockade of
lipolysis, by ameliorating insulin sensitivity, leads to a sig-
nificant reduction of circulating insulin levels (22, 23), raising
the question of whether the enhancement of GH release
observed under those experimental conditions reflects not
only low FFA, but also low insulin levels. To single out the
effect of insulin per se on GH release, independently of FFA,
we designed an experimental protocol in which GH respon-
siveness to GHRH was evaluated at low and similar FFA
levels but progressively increasing insulin levels. The sub-
jects underwent three GHRH tests after acipimox (a drug
inducing an acute reduction of circulating FFA levels) (7, 21)
and during two insulin infusions at increasing rates.
Subjects and Methods
Subjects
Six normal subjects (four men and two women, 25.8 6 1.9 yrs old,
mean 6 se; body mass index, 22.7 6 1.1 kg/m2) were studied after giving
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a written informed consent. The protocol of the study was approved by
the Ethics Committee of the Istituto Scientifico San Raffaele. All subjects
were in good health and had normal routine laboratory examination,
normal endocrine function, normal glucose tolerance after an oral glu-
cose load (75 g), and were taking no medications.
Experimental procedure
According to a single-blind, randomized cross-over protocol, the
subjects underwent, at 1-week intervals, three GHRH tests (50 mg iv, at
1300 h) during: 1) iv 0.9% NaCl infusion (1200 h to 1500 h), with acipimox
(Olbetam, Pharmacia UpJohn, London, UK), 250 mg, being administered
per os (p.o.) at 0700 h and at 1100 h; 2) 0.1 mUzkg21zmin21 euglycemic
insulin clamp, started at 1200 h and continued until 1500 h, with acipi-
mox, 250 mg, being administered p.o. at 0700 h and at 1100 h; 3) 0.4
mUzkg21zmin21 euglycemic insulin clamp, started at 1200 h and con-
tinued until 1500 h, with placebo being administered p.o. at 0700 and
1100 h. Acipimox is a nicotinic acid analog able to inhibit spontaneous,
as well as norepinephrine-, isoprenaline-, and GH-induced lipolysis
(24–26). The rates of insulin infusion were chosen to obtain steady-state
serum insulin levels comparable with those physiologically reached in
normal subjects during the day (27). Insulin infusion was started at
1200 h to obtain steady-state insulin levels and a significant decrease in
plasma FFA levels by the time of GHRH injection (1300 h), as indicated
by a prior pilot study and according to previous reports (28). In test 2,
acipimox was administered to consistently decrease FFA levels to those
observed in test 1 at the time of GHRH injection. In test 3, insulin clamp
was performed under placebo, because in a pilot study, the high insulin
infusion rate was consistently able to decrease FFA levels to those
observed after acipimox.
All subjects were fasted overnight, and the tests were performed in
the recumbent position. Blood samples for evaluation of plasma FFA,
blood glycerol, serum insulin [immunoreactive insulin (IRI)], and serum
GH levels were always drawn at 260 min and just before GHRH ad-
ministration (time zero) and 10, 15, 30, 45, 60, and 120 min after, via an
indwelling catheter inserted into a forearm vein at least half an hour
before the beginning of the sampling period.
The euglycemic insulin clamp was performed as previously reported
(29). Briefly, human insulin (Humulin R, Lilly, Indianapolis, IN) was
given as a prime-continuous infusion by means of a Harvard pump
(Model 975A, Millis, MA). A 20%-dextrose solution was infused by
means of a Harvard servo-controlled infusion system (Model 2990). The
glucose infusion rate adjustment was based on a feedback principle to
maintain euglycemia. Blood samples for evaluation of blood glucose
levels were collected every 5 min during the euglycemic clamp.
Assays
Plasma FFA levels were measured by a spectrophotometric method
adapted to Cobas-Fara 2 (Roche, Basel, Switzerland) using kits supplied
by Italfarmaco (Milano, Italy). Intra- and interassay coefficients of vari-
ation (CVs) were 2.3 and 3.1%, respectively. Blood glycerol levels were
measured by a spectrofluorimetric method adapted to Cobas-Fara 2.
Intra- and interassay CVs were 0.7 and 2.7%, respectively. Serum IRI
levels were measured by RIA using kits supplied by IncStar (Stillwater,
MN). The minimum sensitivity of the assay was 13 pmol/L, and intra-
and interassay CVs were 3.9 and 8.9%, respectively. Serum GH levels
were measured by RIA using kits supplied by Farmos Diagnostic
(Turku, Finland). The minimum sensitivity of the assay was 0.2 mg/L,
and the median intra- and interassay CVs for GH concentrations ranging
from 0.2 to 50 mg/L were less than 9 and 10%, respectively. Blood glucose
levels were measured by a glucose oxidase method (Beckman Glucose
Analyzer II, Beckman Instruments, Fullerton, CA).
Calculations and statistical analysis
Each variable was expressed as the mean 6 se at each time point; the
integrated GH response to GHRH (GH D area under the curve, 0–120
min) was calculated by the linear trapezoidal method. Statistical analysis
was performed by the one-way ANOVA for repeated measures, fol-
lowed by the Student-Newman-Keuls test. P-values less than 0.05 were
considered statistically significant.
Results
No severe side effects were observed during the tests (only
a moderate facial skin rash being evident in one subject after
the first, but not after the second, capsule of acipimox. Figure
1 shows plasma FFA, blood glycerol, serum IRI, and serum
FIG. 1. Plasma FFA, blood glycerol, serum insulin (IRI), and serum
GH levels in six healthy subjects: 1) after acipimox administration
and during NaCl infusion; 2) after acipimox administration and dur-
ing low-dose euglycemic insulin clamp; and 3) after placebo admin-
istration and during high-dose euglycemic insulin clamp. Each time
point represents the mean 6 se. Acx, acipimox.
2240 LANZI ET AL. JCE & M • 1997
Vol 82 • No 7
GH levels before and after GHRH in normal subjects: 1) after
acipimox and during a 0.9% NaCl infusion; 2) after acipimox
and during a 0.1 mUzkg21zmin21 insulin clamp; and 3) after
placebo and during a 0.4 mUzkg21zmin21 insulin clamp, re-
spectively. Mean levels of all the parameters of interest mea-
sured at time of GHRH injection (time zero) are reported in
Table 1. At that time, plasma FFA, blood glycerol, and blood
glucose levels were similar, and serum IRI levels were sig-
nificantly different (P , 0.05) in the three tests. Serum GH
levels were higher after acipimox (alone or combined with
the low-dose insulin clamp) than during the high-dose in-
sulin clamp, although not significantly because of high vari-
ability observed after acipimox.
Figure 2 shows mean plasma FFA, blood glycerol, serum
IRI levels, and mean GH D areas during the 2 h after GHRH
injection (0–120 min). At comparable low plasma FFA and
blood glycerol levels, hyperinsulinemia progressively de-
creased the GH response to GHRH as compared with that
observed after acipimox alone, although the difference was
statistically significant only with the high-dose insulin clamp
(P , 0.05 vs. acipimox alone); in fact, the low-dose insulin
infusion reduced the GH response to GHRH only in four out
of six subjects, whereas the high-dose insulin infusion was
effective in all subjects, independently of sex. Mean blood-
glucose levels were similar in all tests (4.4 6 0.1 vs. 4.6 6 0.1
vs. 4.5 6 0.1 mmol/L, not significant). Considering the three
tests together, a significant negative regression was observed
between the mean serum IRI levels and the GH response to
GHRH (GH D areas) (r 5 20.629, P , 0.01).
Discussion
In lean subjects, pharmacologic blockade of lipolysis by
acipimox enhances the GH response to GHRH (7, 21), caused
by the acute reduction of circulating FFA levels and the
removal of their negative feedback on GH release. Other
direct effects of acipimox, not mediated by an FFA fall, are
unlikely, as shown by Fulcher and co-workers, who observed
no significant GH changes when acipimox was administered
together with a lipid infusion able to maintain stable FFA
levels (30). In the present study, we evaluated the GH re-
sponse to GHRH under conditions of low FFA levels ob-
FIG. 2. Mean plasma FFA, blood glycerol, and serum insulin (IRI) levels, and mean GH D areas within the interval 0–120 min after GHRH
injection in the three tests. Each value represents the mean 6 SE. Acx: acipimox.
TABLE 1. Mean plasma FFA, blood glycerol (glycerol), serum
insulin (IRI), blood glucose, and serum growth hormone GH levels
at the time of GHRH injection (0 min, 50 mg iv) in the six subjects.
Each value represents the mean 6 SE
Parameters
Treatments





FFA (g/L) 0.04 6 0.003 0.02 6 0.005 0.05 6 0.008
Glycerol (mmol/mL) 0.02 6 0.002 0.02 6 0.004 0.03 6 0.009
IRI (pmol/L) 12 6 4 93 6 11a 192 6 24b
Glucose (mmol/L) 4.3 6 0.1 4.5 6 0.1 4.6 6 0.1
GH (mg/L) 5.3 6 2.9 11.7 6 8.4 1.9 6 0.9
a p , 0.05 vs. acx.
b p , 0.05 vs. acx and acx 1 low-dose insulin clamp.
Acx: acipimox.
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tained either by acipimox administration or by insulin infu-
sion at different rates. The results of the present study
indicate that when low plasma FFA levels are attained by
insulin infusion, the GH response to GHRH is significantly
lower than that observed after acipimox. Specifically, we
observed a significant reduction of the GH response to
GHRH at the insulin levels yielded by the high-dose insulin
infusion (150–200 pmol/L), whereas at lower insulin levels
(75–100 pmol/L), the GH response to GHRH, although
lower, was not significantly different from that observed
after acipimox administration. Our data, therefore, suggest
that, independently of FFA, insulin per se is able to exert an
inhibitory effect on GH release. This effect could have a
physiological relevance, because it occurs at insulin levels
(150–200 pmol/L) commonly observed under postprandial
conditions (27), when GH and FFA levels are low. This find-
ing is also in line with previous reports by Diamond and
co-workers (19), who observed a progressive reduction of the
GH response to hypoglycemia, with increasing insulin in-
fusion rates.
Anatomical and experimental data, supporting a possible
negative effect of peripheral insulin on GH release, already
have been reported in the literature. Specific insulin binding
sites have been found in normal rat adenoypophyseal cells
(9), in rat anterior pituitary adenoma cells (10), and in human
pituitary adenoma cells (11); inhibition of GH synthesis and
release, and suppression of GH mRNA content also have
been observed when pituitary cells are exposed to insulin
(11–16). However, the physiological relevance of insulin ac-
tion in the pituitary gland remains doubtful, in light of the
low number of specific insulin receptors present in normal
pituitary cells in comparison with those for insulin-like
growth factors (9, 10). On the other side, insulin could affect
GH release at the level of the central nervous system, i.e. of
the hypothalamus. This hypothesis is supported by experi-
mental evidence. First, the central nervous system can be
reached by peripheral insulin (8), either via a specialized
transport system across the blood brain barrier (8, 31) or by
diffusion in circumventricular organs of the brain lacking
blood brain barrier (8). Specifically, peripheral insulin could
reach the hypothalamus, at least in part, by diffusion in the
median eminence. Second, elevated insulin concentrations,
insulin receptors, and insulin receptor substrate-1 have been
found in the hypothalamus (8, 32–34). Insulin could affect
GH release by increasing levels and release of hypothalamic
catecholamines (35–38), which in turn, may stimulate SRIH
release via b-adrenergic receptors (39). In this regard, the
mediatory role of neuropeptide Y, which is known to stim-
ulate (at least in the rat) hypothalamic SRIH release through
an a1- and b-adrenergic receptor-mediated mechanism (40),
remains a matter of speculation. Finally, insulin could, at
least in part, inhibit GH release through its influence on
potassium homeostasis and circulating amino acid levels. In
fact, by increasing the active membrane transport of potas-
sium into the cells (41) via an activation of membrane (Na1-
K1)-adenosine triphosphatase (ATPase) (42, 43), insulin
could lead to membrane hyperpolarization and reduced GH
release. Modulation of GH release during insulin infusion
also could result from low circulating amino acid levels (44,
45), because amino acids are known to stimulate GH release
(46).
Whichever the mechanism of insulin action on GH release
may be, the data of the present study indicate that in healthy
subjects: 1) acipimox and hyperinsulinemia produce a sim-
ilar decrease in FFA levels caused by their antilipolytic ac-
tivity; 2) under conditions of comparable low FFA levels, the
GH response to GHRH is significantly lower during insulin
infusion than after acipimox. Because acipimox has no direct
effects on GH release (independent of its action on FFA), our
data suggest the existence of an inhibitory effect of insulin on
GH release. This effect may be of physiological relevance,
because it occurs at insulin levels commonly observed during
the day, for instance, during the postprandial period.
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